Chronic care management company Ayble Health is developing a virtual care platform for patients with digestive diseases such as irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD). The company claims 81% of patients who used the platform have improved their IBS and IBD symptoms.
In April 2023, the company launched its D2C app focused on chronic gastrointestinal (GI) conditions. The platform connects patients to expert dietitians who will provide one-to-one care with personalized nutrition plans for 12–16 weeks to improve symptoms. In addition, the platform includes educational tools and resources.
Key customers and partnerships
The company underwent clinical research in seven academic research institutions, including Mayo Clinic, Cleveland Clinic, and the University of Washington. In November 2023, the company partnered with Mayo Clinic to provide a combined virtual and in-person care model for patients with chronic GI conditions.
Funding and financials
The company raised USD 4.6 million in a seed funding round in November 2022, co-led by Upfront Ventures and M13. The new funds were allocated toward clinical research, commercialization, and the development of an ML-driven psychology program.
No investor data is available
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.